Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
The Head Transplant Doctor Will See You Now
Italian neurosurgeon Sergio Canavero, famed for his controversial head‑transplant ambitions, claims a $100 million operation would require an 80‑person surgical team and could eventually give patients a new body. He cites early animal work—rat nerve‑fusion with polyethylene glycol, monkey and dog head grafts—as proof‑of‑concept, while asserting he has already performed transplants on cadavers and non‑human primates. Critics argue the spinal‑cord reconnection is biologically impossible and point to repeated ethical condemnations from medical societies. Canavero now promotes a next‑stage “BRAVE” project to transplant brains into cloned bodies, backed by undisclosed wealthy investors.
Regulatory Education for Industry (REdI) Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products - 05/19/2026
The FDA’s Regulatory Education for Industry (REdI) Annual Conference will take place May 19‑20, 2026, offering both virtual and in‑person sessions at the White Oak Campus in Maryland. The two‑day program features three dedicated tracks—drugs, devices, and biologics—allowing participants to...
How to Integrate PRN Staff Into Your Existing Care Team
Integrating PRN nurses into existing care teams requires more than ad‑hoc scheduling; it demands structured onboarding, clear role definitions, and robust communication channels. Facilities should assign permanent mentors, provide concise orientation, and grant access to electronic health records and equipment....
FDA Approves Avlayah as Treatment of Hunter Syndrome
Denali Therapeutics received accelerated FDA approval for Avlayon (tividenofusp alfa‑eknm), the first enzyme replacement therapy designed to cross the blood‑brain barrier for Hunter syndrome. The approval is based on a phase 1/2 trial of 47 boys up to 18 years, showing...
$125M and a Cap Table That Reads Like a Who’s Who of Healthcare VC: What Qualified Health’s Series B Actually...
Qualified Health announced a $125 million Series B round, bringing its total funding to $155 million and led by NEA alongside a slate of top health‑tech investors. The company offers an enterprise‑wide AI infrastructure platform that replaces fragmented point‑solution approaches. Early adopters such...
FY 2025 GDUFA Science and Research Report
The FDA’s Center for Drug Evaluation and Research released its FY 2025 GDUFA Science & Research Report, detailing more than 50 funded projects across eight priority scientific initiatives. The program targets bioequivalence, manufacturing standards, and advanced analytical methods to streamline abbreviated...
Patent Certifications and Suitability Petitions
Under the Hatch‑Waxman law, generic manufacturers must file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed to obtain FDA approval. The first substantially complete ANDA with such a certification secures a 180‑day exclusivity period,...
This Cutting-Edge Treatment Hit the Rewind Button On Aging, Scientists Say
Researchers at Longeveron reported that a single infusion of laromestrocel, a mesenchymal stem‑cell therapy derived from donors aged 14‑18, significantly boosted mobility in frail seniors. In a double‑blind trial of about 150 participants aged 70‑85, the highest dose (200 million cells)...
Cardiologists Use Endovascular Device for Brain Aneurysms to Treat High-Risk Heart Patients
Mayo Clinic interventional cardiologists and radiologists have repurposed Terumo's WEB SLS II intrasaccular flow disruptor—originally approved for intracranial bifurcation aneurysms—to treat saccular coronary aneurysms. The first case involved a 74‑year‑old patient undergoing aortic valve replacement and bypass surgery, where the device achieved...
New Zealand Trains 514 Mental‑Health Professionals, Cuts Wait Times
Mental Health Minister Matt Doocey said 514 new mental‑health and addiction workers were trained in the past year, exceeding the 500‑person target. The expanded workforce has helped reduce primary‑care wait times to one week and specialist wait times to three...
ACC/AHA 2026 Guideline Calls for Cholesterol Treatment Starting at Age 30
The American College of Cardiology and American Heart Association released a 2026 cholesterol guideline that shifts focus to earlier risk assessment and treatment, recommending clinicians consider medication as early as age 30. The update introduces a new PREVENT risk calculator...
IRA Drug Provisions Linked to Significant Drop in Medicare Medication Nonadherence
New research shows the Inflation Reduction Act’s 2024 Medicare drug caps and expanded low‑income subsidies have materially reduced cost‑related medication nonadherence. A JAMA Internal Medicine study found a 4.9‑percentage‑point drop overall, rising to 7.8 points among beneficiaries with multiple chronic...
IP Considerations Following FDA Announcement on Flexibility for Cell and Gene Therapies
The FDA announced new guidance that expands flexibility in chemistry, manufacturing, and controls (CMC) for cell and gene therapies (CGTs) across their development lifecycle. Sponsors can now defer full cGMP compliance until later trial phases and make iterative manufacturing changes...
FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
The FDA granted accelerated approval to Avlayah (tividenofusp alfa‑eknm), a weekly IV infusion, for treating neurologic manifestations of Hunter syndrome in pediatric patients weighing at least 5 kg. The approval is based on a phase 1/2 trial that demonstrated a 91% average...
ACA Subsidy Cliffs Are Back and Costing Clients Thousands
For the first time in five years, the ACA’s enhanced premium tax credits expire at the end of 2025, restoring the pre‑pandemic subsidy structure. Households earning just above 400% of the federal poverty level—about $62,600 for an individual or $84,600...
Kansas House Moves Forward on Bill to Tighten PBM Rules and Lower Drug Prices
The Kansas House of Representatives approved a bill that would tighten regulations on pharmacy benefit managers (PBMs) to help lower prescription‑drug prices. The measure now heads to the Senate, where it could reshape how insurers negotiate drug rebates and pricing.
Leveraging the Full Potential of Regenerative Medicine Requires a Proactive Approach
Regenerative medicine promises to shift healthcare from a reactive model to proactive disease modification by targeting early biological drivers of chronic degeneration. Cell‑based therapies such as mesenchymal stromal/stem cells (MSCs) can modulate inflammation, immune signaling, and tissue repair, showing benefits...
‘Uphill Battles on Many Fronts’: HDG CEO on Supercharged Nursing Home Payment Pressures, Staffing Challenges
Health Dimensions Group (HDG) CEO Erin Shvetzoff Hennessey warned that skilled nursing facilities (SNFs) are facing "supercharged" payment pressures from Medicaid funding challenges, a drop in private‑pay residents, and managed‑care reimbursement cuts. The financial squeeze coincides with rising resident acuity...
FDA Issues Early Alert for Certain Dialysis Devices From B. Braun Medical
The U.S. Food and Drug Administration issued an early alert for B. Braun Medical’s Streamline Airless System Hemodialysis Bloodlines and B3 Low Volume Bloodlines after testing revealed a resin change that caused tiny air bubbles to cling to the arterial line...
Why Revenue Cycle Teams Must Prepare for Extended Downtime in the Age of Cyber Threats
Healthcare providers face escalating ransomware and cloud‑outage threats that can instantly cripple revenue cycle operations, halting claim submissions and cash flow. Recent incidents, such as the Change Healthcare clearinghouse outage and a regional system’s backup encryption, exposed critical blind spots...
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine — Episode 248
The Xtalks Life Science Podcast featured Dr. Steve Levine, Chief Patient Officer at Compass Pathways, discussing the company’s push to develop psilocybin‑based therapies for treatment‑resistant depression (TRD). Levine, a board‑certified psychiatrist and founder of Actify Neurotherapies, highlighted the clinical promise...
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
The FDA issued a warning letter to ImmunityBio for misleading promotional claims about its bladder‑cancer drug Anktiva, triggering a roughly 26 percent drop in the company’s shares and giving it 15 days to submit a corrective plan. In parallel, Merck announced a...
GlycoNet – Sugar-Based Vaccine Against Bacterial Diarrhea Shows Promise in Phase 1 Trial
Researchers at the University of Guelph announced that their sugar‑based vaccine candidate against Campylobacter jejuni demonstrated safety and immunogenicity in a small Phase 1 human trial. Participants experienced only mild side effects, and the formulation generated measurable antibody responses even at...
Low-Light Difficulties Based on Severity of Visual Field Loss
A recent Australian study uncovered a two‑phase relationship between integrated visual‑field loss and low‑light difficulties in glaucoma patients. Below an IVF total‑deviation of –6.3 dB (or sensitivity‑based IVF of 21.7 dB), LLQ scores drop sharply, indicating functional impairment. Inferior field defects were...
Anavex Sinks After Pulling Alzheimer's Filing in EU
Anavex Life Sciences withdrew its European marketing authorisation application for blarcamesine, an add‑on therapy for early‑stage Alzheimer’s, after the EMA’s CHMP signaled a likely negative opinion. The committee criticized the trial’s efficacy data, methodological flaws, and safety reporting, including concerns...
Florida Restores Access to Low-Cost H.I.V. Medications After Uproar
Florida enacted a short‑term bill allocating roughly $31 million to keep its AIDS Drug Assistance Program (ADAP) operational, averting a gap in coverage for more than 12,000 residents. The funding reversal follows a March 1 policy that tightened eligibility and threatened to...
Long-Term Neuropathy Common in Breast Cancer After Chemotherapy
New research of 1,493 breast‑cancer survivors aged 65 and older shows that more than 60 % of those who received chemotherapy report moderate to severe neuropathy five years after treatment, compared with 36 % of non‑chemo patients. The risk is driven largely...
Health Care Affordability Crisis: Lessons From the NYC Nursing Strike
A historic nursing strike involving nearly 15,000 New York workers has exposed a deep health‑care affordability crisis. Hospitals such as NewYork‑Presbyterian and Mount Sinai are spending roughly $32,000 per nurse on health benefits, while procedure costs like hip replacements soar to...
More Changes Ahead for Takeda with New CEO Set to Take Reins
Takeda Pharmaceutical announced that Julie Kim will assume the role of chief executive, continuing the company’s multi‑year restructuring agenda. The board approved a new phase of the transformation, emphasizing the rollout of upcoming product launches and accelerating late‑stage pipeline development....
Should Nonprofit Hospitals Use Tax Breaks To Name Sports Stadiums?
Nonprofit health systems, shielded by $37‑$54 billion in annual tax exemptions, are allocating unrestricted surplus to high‑profile stadium naming‑rights deals, such as Texas Health’s $88 million agreement for a new venue in Mansfield, Texas. While these sponsorships boost brand visibility, charity‑care spending...
Why Aerobic Exercise, Not Just Strength Training, Matters on GLP-1 Drugs
A secondary analysis of a Danish year‑long trial examined 193 adults on the GLP‑1 agonist liraglutide with or without a structured aerobic exercise program. Participants first lost an average of 29 pounds on a very‑low‑calorie diet, then were assigned to four...
Medicare To Pay Docs To Reduce Falls By Seniors While WH Curbs Other Efforts
The Centers for Medicare & Medicaid Services announced the Long‑term Enhanced ACO Design (LEAD) program, which will begin in January 2027 and pay participating physicians incentives to prevent falls among frail seniors and disabled adults. LEAD uses fixed episode payments...
Drug Quality Sampling and Testing Programs
The FDA’s Center for Drug Evaluation and Research (CDER) released its FY 25 Drug Quality Sampling and Testing results, showing that the vast majority of tested pharmaceuticals met USP specifications. The program uses a risk‑based, data‑driven approach introduced in 2018 to...
Kiran Batheja: Collaboration Yields Results
HFMA’s "Lead Now" initiative capitalized on the One Big Beautiful Bill Act of 2025, driving unprecedented growth and engagement across the healthcare finance sector. Membership surged to over 145,000—the highest in its 80‑year history—while more than 1,080 volunteers delivered 197,000...
Summit Sparks Breakthroughs: AI, Gene Therapy, CRISPR, mRNA
One thing that really makes the in-person summits we run at STAT so amazing: the people in the room. Here's what happened when we asked some of them for the last big breakthrough they saw. Featuring: the infectious @DrBlytheAdamson, genomcis pioneer...
Health Experts Warn EPA Rollback Threatens Public Health
"We health professionals must call urgent attention to this silent but deadly assault [EPA dismantling ] on American's health...." @NEJM https://t.co/FJYbZh5O1m https://t.co/hajEmMWHTs
BREAKING: Senate Investigation Finds Federal Officials Buried COVID-19 Vaccine Stroke Risk
A Senate investigation led by Sen. Ron Johnson uncovered that federal health officials identified a statistically significant ischemic stroke risk associated with the Pfizer COVID‑19 booster for adults 65 and older as early as November 2022. Internal HHS records show...
AI-Driven Humanoid Robots Promise Universal, Elite-Level Healthcare
Humanoid robots + AI will mean everyone on Earth has access to better medical care than the richest person alive today. THAT is what abundance looks like.
Blueprint for Affordable, Accessible AAV Gene Therapy
When people ask "How can we make #AAV #GeneTherapy accessible and affordable" --> this is how 👇
2026 Memory Care Innovation Awards Entries Due April 3
The 2026 Memory Care Innovation Awards are accepting final entries until April 3, 2026. The program honors high‑performing employees with at least seven years of experience who drive cognitive‑care advances across home‑health, hospice, senior‑living and related sectors. Awardees receive dual press‑release recognition,...
World Health Day 2026: Stand with Science and Global Health Equity
World Health Day 2026, observed on April 7, adopts the theme “Together for Health, Stand for Science,” urging global unity around science‑driven health solutions. The WHO highlights One Health—linking human, animal and environmental health—and convenes two flagship events: the One Health...
How Seaport Is Hedging Against Failure in Phase 2b Depression Study
Seaport Therapeutics is embedding a fail‑safe mechanism into its Phase 2b trial of SPT‑300, an experimental therapy for major depressive disorder. The study will enroll roughly 300 patients at multiple U.S. sites and uses an adaptive design that can halt...
ICHRAs, Local Health Networks Empower Employees to Access Better Care
Employers are rapidly moving from traditional defined‑benefit health plans to defined‑contribution models, chiefly through Individual Coverage Health Reimbursement Arrangements (ICHRA). Mercer projects average employer healthcare spending to hit $18,500 per employee by 2026, making cost predictability a priority. Employees cite...
Bill Screening Student Athletes for Heart Conditions Clears Committee
Connecticut's Public Health Committee unanimously approved Senate Bill 194, mandating cardiac screening forms for every student athlete in intramural and interscholastic programs. The form probes chest pain during exercise, unexplained fainting, prior cardiac events, and family heart‑disease history. Students who...
If You’re On GLP-1s Like Wegovy You Need to Know This Before You Get On a Plane
GLP‑1 drugs such as Wegovy and Mounjaro require cool storage, yet airlines do not offer refrigeration for passenger medication. Flight attendants cannot place these injectables in aircraft fridges, which are intended for food and may vary in temperature. Travelers must...
BREAKING STUDY: COVID-19 “Vaccines” DISRUPT THE BLOOD-BRAIN BARRIER — 63 Serious Brain & Spinal Cord Safety Signals Identified
A recent Substack post cites a study claiming COVID‑19 mRNA vaccines increase reports of rare neurological disorders by dozens to thousands of times compared with flu shots, based on VAERS data from 1990‑2024. The post lists specific conditions such as...
FDA Approves Relacorilant with Nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The FDA has approved relacorilant (Lifyorli), a glucocorticoid‑receptor antagonist, in combination with nab‑paclitaxel for adults with platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received up to three prior regimens, including bevacizumab. The approval is based on...
How Policy Changes Are Shaping Patient Support Programs
Pharmaceutical firms are pivoting from healthcare providers to patients as the primary focus of their support programs, a shift accelerated by recent policy changes. The expiration of enhanced ACA subsidies and the One Big Beautiful Bill are reducing insurance enrollment, leaving millions uninsured...
EFF Sues for Answers About Medicare's AI Experiment
The Electronic Frontier Foundation has filed a Freedom of Information Act lawsuit against the Centers for Medicare & Medicaid Services to obtain records on the WISeR program, a multi‑state Medicare pilot that uses artificial intelligence to evaluate prior‑authorization requests. WISeR,...